* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
Solid tumors present a complex and highly heterogeneous setting for Proteolysis Targeting Chimera (PROTAC) research. Unlike conventional occupancy-driven inhibitors, PROTACs are designed to bring a protein of interest (POI) into proximity with an E3 ubiquitin ligase, promoting ubiquitination and proteasome-mediated protein degradation. For solid tumor programs, this mechanism offers a powerful way to investigate oncogenic drivers, signaling scaffolds, transcriptional regulators, mutant proteins, and resistance-associated targets whose biological function may not be fully addressed by inhibition alone.
However, successful PROTAC development for solid tumors requires more than connecting a target ligand, an E3 ligase ligand, and a linker. Researchers must consider tumor lineage, target dependency, mutation status, cellular permeability, E3 ligase expression, ternary complex formation, degradation kinetics, selectivity, tumor-relevant models, and downstream pathway response. BOC Sciences provides integrated PROTAC solutions for pharmaceutical, biotechnology, and research organizations developing degraders for lung, breast, prostate, colorectal, pancreatic, ovarian, brain, and other solid tumor research programs.
Our service platform covers target feasibility assessment, POI ligand strategy, E3 ligase selection, linker optimization, custom PROTAC synthesis, cell-based degradation profiling, functional validation, selectivity assessment, and in vivo research evaluation. By integrating medicinal chemistry, structural biology, cancer biology, and degradation-focused assay design, BOC Sciences helps clients translate solid tumor biology into rational PROTAC development strategies with clearer decision points and more reliable experimental outcomes.
Services
BOC Sciences' Comprehensive PROTAC Services for Solid Tumor Research
Solid Tumor Target Feasibility and Degradability Assessment
A strong solid tumor PROTAC program begins with selecting a target whose biology, expression pattern, localization, ligandability, and degradation relevance support a rational degrader strategy. We evaluate tumor dependency data, mutation background, available chemical matter, target turnover, subcellular localization, and assay feasibility to help clients determine whether degradation is likely to provide meaningful biological insight.
Target biology review across solid tumor indications and cellular contexts
Assessment of mutant proteins, oncogenic drivers, transcriptional regulators, kinases, and scaffold proteins
Early identification of degradability risks, model requirements, and assay readout options
POI Ligand and Warhead Strategy for Solid Tumor Targets
The POI-binding ligand determines whether a PROTAC can engage a tumor-relevant target without losing binding activity after derivatization. BOC Sciences supports the evaluation of known inhibitors, covalent ligands, reversible ligands, allosteric binders, peptide ligands, and fragment-derived starting points, with attention to exit vector selection, binding-site tolerance, mutation coverage, and solid tumor pathway relevance.
Warhead selection for kinases, nuclear receptors, epigenetic proteins, KRAS, EGFR, BET proteins, and other oncology targets
Covalent and reversible binding strategy comparison for mutation-defined tumor targets
Binding-site and derivatization-position assessment to preserve target engagement
E3 Ligase Recruitment Strategy
E3 ligase selection can strongly influence degradation potency, tumor-cell selectivity, and target compatibility. We help clients compare cereblon (CRBN), von Hippel-Lindau (VHL), inhibitor of apoptosis protein (IAP), mouse double minute 2 homolog (MDM2), and alternative E3 ligase recruitment strategies based on target location, tumor model context, E3 expression, ligand availability, and expected ternary complex behavior.
Comparative assessment of CRBN-, VHL-, IAP-, and MDM2-recruiting approaches
E3 ligase expression and cellular localization considerations for solid tumor models
E3 ligand-linker conjugate strategy for focused degrader library construction
Linker Design and Physicochemical Optimization
Linker architecture is often the decisive factor separating a potent binder from a productive degrader. For solid tumor PROTACs, linker length, rigidity, polarity, exit vector, conformational freedom, and molecular property balance must be optimized together to support ternary complex formation, cell penetration, and degradation durability.
PEG, alkyl, heterocyclic, rigid, semi-rigid, and cleavable linker strategies
Structure-degradation relationship analysis using degradation concentration 50 (DC50) and maximum degradation (Dmax)
Optimization of polarity, flexibility, molecular size, and cellular exposure
Custom PROTAC Synthesis and Analog Expansion
BOC Sciences provides custom synthesis support for solid tumor PROTAC programs, from initial degrader design to focused analog expansion. We prepare POI ligand-linker intermediates, E3 ligand-linker conjugates, and complete bifunctional degraders, enabling clients to compare E3 recruiters, linker families, attachment sites, and warhead variants in a systematic manner.
Parallel synthesis of solid tumor degrader analog sets
Synthetic route exploration for complex bifunctional molecules
Chemistry iteration guided by degradation potency, permeability, and cellular response
Cell-Based Degradation and Functional Evaluation
Degradation activity must be confirmed in tumor-relevant cellular systems, not inferred from binding affinity alone. We support in vitro and cell-based assays to quantify target protein loss, degradation kinetics, dose response, pathway modulation, selectivity, and functional consequences across solid tumor cell models selected according to target expression, mutation background, and project objectives.
Our Solutions for Solid Tumor PROTAC Development Challenges
Solid tumor PROTAC projects often require coordinated decisions across target biology, tumor model selection, molecular design, assay configuration, and data interpretation. BOC Sciences helps clients reduce uncertainty by connecting rational design with experimentally grounded validation, allowing each optimization cycle to answer a clear technical question.
Solution for Target Selection and Tumor Context
Many solid tumor targets are attractive biologically but difficult to degrade because of poor ligandability, unsuitable localization, rapid compensatory signaling, or limited assay access. We address this by evaluating tumor dependency, target expression, mutation status, available ligands, degradation precedent, and model suitability. This helps clients prioritize targets where PROTAC-mediated protein removal is technically feasible and biologically informative.
Solution for Productive E3–Target Pairing
A PROTAC may fail when the selected E3 ligase cannot form a productive ternary complex with the POI in the chosen tumor cell context. We compare E3 recruitment options, analyze ligand exit vectors, and design molecules that test multiple POI–PROTAC–E3 geometries. When early degraders show weak activity, we use ternary complex and pathway-dependence data to identify whether the limiting factor is E3 selection, linker geometry, target engagement, or cellular exposure.
Solution for Permeability and Molecular Property Balance
Solid tumor PROTACs are often large, flexible, and polar, which can reduce intracellular exposure. BOC Sciences supports molecular property optimization through linker redesign, polarity adjustment, conformational constraint, and cellular permeability testing. Our integrated workflow uses PROTAC cellular permeability assay data alongside degradation results to distinguish insufficient exposure from poor degradation mechanism.
Solution for Mechanistic Validation and Selectivity
Apparent target loss can arise from proteasome-dependent degradation, pathway feedback, reduced expression, or nonspecific cellular stress. We design validation studies using dose-response analysis, time-course profiling, competition experiments, proteasome-dependence evaluation, ubiquitination monitoring, and PROTAC selectivity evaluation. These studies help clients interpret degradation data with confidence and prioritize molecules with stronger target-focused profiles.
Build Better PROTAC Programs for Solid Tumor Targets with BOC Sciences!
From target feasibility and E3 ligase strategy to custom synthesis, cell-based degradation profiling, and tumor model evaluation, BOC Sciences provides tailored support for solid tumor PROTAC research. Our interdisciplinary expertise helps clients convert complex oncology biology into actionable degrader design and optimization strategies.
Our PROTAC Solutions Support Diverse Solid Tumor Research Teams
Pharmaceutical Discovery Teams
Pharmaceutical research groups often need a systematic way to evaluate whether degradation can outperform inhibition for oncogenic drivers, mutant signaling proteins, and resistance-associated targets. BOC Sciences supports target assessment, degrader design, synthesis, assay development, and iterative optimization for solid tumor discovery programs.
Biotechnology Companies
Biotechnology companies may require rapid proof-of-concept data to support a new degradation strategy, compare target classes, or validate tumor-context dependency. We provide flexible research modules covering warhead evaluation, E3 ligand selection, analog synthesis, degradation screening, and functional readout design.
Academic and Translational Research Laboratories
Academic teams use PROTACs to interrogate solid tumor biology, define target dependency, and explore protein-removal phenotypes that cannot be fully captured by inhibitors. We help these groups access degrader design, synthesis, and mechanism-focused assays suitable for hypothesis-driven research.
CROs and Technical Platforms
Contract research organizations and technical platforms may need specialized PROTAC chemistry or degradation biology support to complement internal capabilities. BOC Sciences offers modular cooperation models for ligand design, linker optimization, custom synthesis, cell-based evaluation, and data interpretation.
End-to-End Workflow for Solid Tumor PROTAC Development
01
Inquiry and Project Background Review
Collect information about the target protein, tumor type, mutation status, available ligands, preferred E3 ligase strategy, assay expectations, and project-stage objectives.
02
Target Feasibility and Model Selection
Evaluate target degradability, tumor-cell expression, pathway relevance, ligand availability, and suitable cellular or tumor model systems for degradation readouts.
03
PROTAC Design Strategy
Define the POI ligand, E3 ligase ligand, linker families, attachment sites, analog scope, and key design hypotheses for a focused solid tumor degrader series.
04
Synthesis Planning and Compound Preparation
Prepare POI ligand-linker intermediates, E3 ligand-linker conjugates, and complete PROTAC analogs through routes designed for efficient comparison of multiple molecular variables.
05
Primary Degradation Screening
Test PROTAC candidates in tumor-relevant cell models using dose-response and time-course designs to determine target protein reduction, DC50, Dmax, and degradation kinetics.
06
Mechanistic and Functional Validation
Confirm proteasome dependence, target engagement, ubiquitination, pathway modulation, and tumor-cell functional response using assays aligned with the target biology.
07
Optimization and Selectivity Assessment
Refine warhead, linker, E3 recruitment, and molecular properties based on degradation potency, selectivity, permeability, pathway response, and structure-degradation relationships.
08
Data Reporting and Next-Step Recommendation
Deliver experimental data, compound information, degradation profiles, interpretation of key findings, and recommendations for the next design, synthesis, or validation cycle.
Capabilities
Key Capabilities for Solid Tumor PROTAC Programs
Tumor-Relevant Target Strategy
We support PROTAC design for solid tumor targets including mutant kinases, KRAS-family proteins, nuclear receptors, epigenetic regulators, transcription-associated proteins, and signaling scaffolds.
E3 Ligase Selection Logic
Our team evaluates E3 ligase options based on tumor model context, target localization, ligand availability, ternary complex potential, and degradation selectivity.
Integrated Chemistry and Biology
BOC Sciences connects custom synthesis, linker optimization, cell-based degradation assays, and mechanistic validation to guide rational degrader optimization.
Actionable Degradation Data
We provide degradation potency, Dmax, kinetics, selectivity, permeability, and pathway-response data to support clear project decisions.
Applications
Applications of PROTACs in Solid Tumor Research
Lung Cancer and EGFR/KRAS-Driven Tumor Models
Development of degraders for EGFR, KRAS, ALK, ERK, and downstream signaling nodes
Evaluation of target depletion effects on transcriptional biomarkers and cell-state transitions
Selectivity profiling to distinguish target-driven degradation from broad transcriptional stress
Case Study
Client Success Stories: PROTACs for Solid Tumors
Project Background
A biotechnology research team had an epidermal growth factor receptor (EGFR)-binding inhibitor scaffold with strong enzymatic potency but limited confidence that inhibition alone could support its mechanism-focused solid tumor program. The client wanted to explore EGFR degradation in a mutation-defined lung tumor model, compare CRBN- and VHL-recruiting designs, and identify whether target protein removal could produce clearer downstream pathway modulation.
Our Support
BOC Sciences first reviewed the EGFR ligand binding mode and identified two solvent-exposed positions suitable for linker attachment. We designed 32 PROTAC candidates across CRBN- and VHL-recruiting formats using PEG, alkyl, and semi-rigid heterocyclic linkers ranging from 6 to 15 atoms. After synthesis, candidates were evaluated in EGFR-mutant lung tumor cell models using 6 h, 16 h, and 24 h treatment windows. The first screening round showed that long PEG linkers preserved binding but generated weak degradation, suggesting nonproductive ternary complex geometry. We then prioritized semi-rigid linkers and adjusted the E3 ligand exit vector. The optimized analog achieved EGFR Dmax above 75% at 24 h under the selected assay conditions, with a measurable reduction in downstream phosphorylation markers and improved separation between degradation activity and nonspecific cellular stress.
Client Testimonial
BOC Sciences helped us understand why our first EGFR degrader ideas were not translating into protein loss. Their team connected structural design, linker chemistry, and degradation assay interpretation into a practical optimization path.
Project Background
A drug discovery group was investigating KRASG12C degradation as an alternative strategy for a solid tumor signaling program. The client had a covalent KRASG12C ligand and several preliminary PROTAC concepts, but early compounds showed inconsistent target reduction and a narrow cellular activity window. They needed support to redesign the PROTAC architecture, evaluate E3 ligase compatibility, and generate interpretable degradation data.
Our Support
We evaluated the covalent warhead orientation and found that the original linker attachment site likely restricted productive positioning of the recruited E3 ligase. BOC Sciences designed 28 new candidates using two E3 ligase recruitment strategies and four linker families, including short alkyl, PEG, triazole-containing, and constrained heterocyclic linkers. Primary screening in a KRASG12C-positive lung tumor cell model showed that several short alkyl designs retained cellular engagement but failed to produce durable degradation. A second optimization round introduced a more polar semi-rigid linker, which improved degradation consistency and reduced the high-concentration hook-effect window. The best candidate produced approximately 60% target reduction at 16–24 h under optimized conditions and provided the client with a defined molecular template for further structure-degradation relationship expansion.
Client Testimonial
The BOC Sciences team did more than synthesize KRAS degrader analogs. They helped us identify the real bottleneck, redesign the linker and E3 recruitment strategy, and turn inconsistent early data into a focused optimization campaign.
Why Us
Why Choose BOC Sciences for Solid Tumor PROTAC Development?
Integrated Solid Tumor Degrader Expertise
We combine cancer target biology, PROTAC design, custom synthesis, degradation assays, and model-specific evaluation to support complete solid tumor degrader programs.
Target- and E3-Matched Design Logic
Our team evaluates target localization, tumor-cell expression, E3 ligase context, ligand geometry, and ternary complex potential before committing to synthesis.
Flexible Modular Service Models
Clients can request single-service support, such as linker optimization or degradation assays, or end-to-end PROTAC development from target assessment to optimized analog series.
Data-Driven Optimization
We connect synthetic chemistry, permeability, degradation potency, selectivity, and functional pathway data to guide each iteration with clear decision criteria.
Mechanism-Focused Validation
Our validation workflows help determine whether target reduction is consistent with target engagement, ubiquitination, proteasome dependence, and expected downstream response.
Clear Reporting and Practical Recommendations
BOC Sciences provides organized data packages, structure-degradation interpretation, and actionable recommendations for the next synthesis, screening, or optimization cycle.
PROTACs, or Proteolysis Targeting Chimeras, induce proximity between a target protein and an E3 ubiquitin ligase, leading to ubiquitination and proteasome-mediated degradation of the target protein. In solid tumor research, this strategy is valuable for studying oncogenic drivers, transcriptional regulators, epigenetic proteins, and resistance-associated proteins that may be difficult to modulate with conventional inhibitors. By reducing the protein level itself rather than only blocking catalytic activity, PROTACs help researchers evaluate how target removal affects tumor cell proliferation, apoptosis, pathway remodeling, and resistance phenotypes.
How should solid tumor PROTAC targets be selected?
Target selection for solid tumor PROTAC programs should consider disease relevance, protein expression level, subcellular localization, available ligand information, degradation-linked phenotype, and differential expression between tumor and non-tumor cell models. Promising targets usually show clear tumor dependency and a measurable degradation window in relevant cellular systems. BOC Sciences can support early target assessment by evaluating degradability, ligand derivatization feasibility, E3 ligase compatibility, and functional assay design, helping research teams reduce unproductive synthesis efforts and prioritize technically actionable targets.
Why is solid tumor PROTAC optimization challenging?
Solid tumor PROTAC optimization is complex because bifunctional degraders must balance target binding, E3 ligase recruitment, linker geometry, cellular permeability, intracellular exposure, and ternary complex formation. High molecular weight, excessive polarity, or overly flexible linkers may weaken cell entry and reduce degradation efficiency. Therefore, optimization should not rely only on binding affinity. Researchers often need to compare structure–activity relationships and structure–degradation relationships together, using DC50, Dmax, degradation kinetics, pathway modulation, and tumor cell phenotype data to guide each design cycle.
How is true PROTAC-mediated degradation confirmed?
True PROTAC-mediated degradation should be confirmed by connecting target protein reduction with ubiquitin–proteasome pathway engagement, dose dependence, time dependence, and downstream functional effects. Common evaluation methods include Western blot, targeted protein quantification, proteomic profiling, cell viability analysis, and pathway marker detection. Mechanism-focused controls, such as proteasome inhibition, competitive ligand blocking, or E3 ligase-related comparison, help distinguish target degradation from nonspecific cellular stress. For solid tumor models, it is also important to compare multiple cell lines with different target and E3 ligase expression backgrounds.
What support can BOC Sciences provide for PROTACs for solid tumors?
BOC Sciences provides integrated support for solid tumor PROTAC research, covering target feasibility assessment, ligand modification, E3 ligase selection, linker design, PROTAC synthesis, in vitro degradation validation, and tumor cell-based functional evaluation. For solid tumor-focused projects, we help clients select suitable cell models, design focused degrader libraries, establish degradation and phenotype readouts, and interpret potency, selectivity, permeability, and functional response data together. This integrated approach supports clearer decision-making and more efficient optimization of early-stage degrader candidates.
Quick Inquiry
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
We invite you to contact us at or through our contact form above for more information about our services and products.
Tumor-Relevant Target Strategy
